AKT1 and non-small cell lung carcinoma: The sensitivity of EGFR-TKI in EGFR-mutated cancer cells cultured with COLI was investigated when COLI activated mTOR via Akt and ERK1/2-independent pathway in NSCLC, leading to EGFR-TKI resistance.